BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241112
DTEND;VALUE=DATE:20241114
DTSTAMP:20260515T144750
CREATED:20240719T120908Z
LAST-MODIFIED:20240719T120908Z
UID:39429-1731369600-1731542399@www.pharmajournalist.com
SUMMARY:Autoimmunity Pharma & Biotech Partnering Summit
DESCRIPTION:Spurred by George Schett and Andreas Mackensen’s remarkable CAR-T results in SLE\, the immunotherapy revolution for autoimmune diseases is the next “million-dollar question”. \nThe Autoimmunity Pharma & Biotech Partnering Summit is the only event of its kind\, laying enabled partnering on top of hyper-relevant scientific discussion specifically for immune reset and reconstitution therapies. \nVIEW THE FULL EVENT GUIDE \n60+ attending companies across modalities so pharma can decide which horse to back in this quickly evolving space \n1-2-1 meetings bookable via the partnering portal for efficient and high yielding conversations between decision makers \n15 big pharma leads across business development\, search and evaluation\, immunology research and venture giving the best\, most comprehensive opportunity to meet the full teams assessing due diligence and asset synergy \n100% alignment on interests and intentions\, increasing the surface area for synergy in research and collaboration goals \nSecure your place here or get in touch with the team – info@hansonwade.com
URL:http://www.pharmajournalist.com/event/autoimmunity-pharma-biotech-partnering-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com or Partnership Enquiries: sponsor@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241112
DTEND;VALUE=DATE:20241115
DTSTAMP:20260515T144750
CREATED:20240805T120321Z
LAST-MODIFIED:20240805T120321Z
UID:39498-1731369600-1731628799@www.pharmajournalist.com
SUMMARY:Hit ID Summit
DESCRIPTION:Discover the future of drug discovery at the inaugural Hit ID Summit! As chemical libraries and hit screening methods—including DNA-encoded libraries\, high-throughput screening\, fragment-based screening\, and AI—continue to evolve\, now is the time for medicinal chemists\, computational chemists\, and drug discovery leaders and innovators to unite at a dedicated forum. This unique event presents the opportunity to share innovative ideas and actionable insights that will revolutionize hit finding strategies and propel the entire drug development process forward. From delving into the latest hit-finding technologies and methodologies\, bridging the gap from target identification to molecule discovery and transforming hits into promising leads. \nJoin us for an unmissable experience where the biggest names in pharma and biotech come together including AstraZeneca\, Bristol Myers Squibb\, GlaxoSmithKline\, Insitro\, Sanofi & more. This is your chance to stay ahead of the curve and drive innovation in your hit identification and drug discovery strategies. \nDon’t miss out on this unique opportunity to network with over 50 hit strategy specialists and drug discovery experts. With insights from industry giants like AbbVie\, AstraZeneca\, Novartis\, Pfizer\, Sanofi\, and UCB\, gain invaluable knowledge and forge meaningful connections that will take your work to the next level. \nTo know more visit: https://ter.li/fifhhn%20
URL:http://www.pharmajournalist.com/event/hit-id-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241112
DTEND;VALUE=DATE:20241115
DTSTAMP:20260515T144750
CREATED:20240815T164037Z
LAST-MODIFIED:20240815T164037Z
UID:39582-1731369600-1731628799@www.pharmajournalist.com
SUMMARY:8th Dermatology Drug Development Summit
DESCRIPTION:The advanced therapy immuno-inflammatory dermatology market is undergoing unprecedented expansion\, as Johnson & Johnson make a $3.35B play for bispecific candidates\, Alumis secured $259M series C and Galderma\, Incyte\, and Eli Lilly unveil late-breaking data. \nWith a fast-evolving drug development landscape\, remaining at the forefront of promising targets is now more crucial than ever. That’s why we’re delighted to announce the return of the 8th Dermatology Drug Development Summit (November 12-14 | Boston\, MA)\, the definitive industry-led forum uniting 130+ large pharma\, biotech\, and clinician KOLs to discover and develop best-in-class drugs for immuno-inflammatory skin disease. \nExplore the end-to-end conference program here: https://ter.li/5j7wx4 \nFeaturing 30+ expert speakers from the likes of Alys Pharmaceuticals\, LEO Pharma\, Incyte and AbbVie\, program highlights include: \n\n2 NEW tracks on Discovery & Translation to the Clinic and Clinical & Commercial Strategy\, providing more depth of content supporting disease pathogenesis understandings and novel target validation\, through demonstrating durable clinical efficacy whilst navigating nuanced market access challenges\n4 hands-on workshops pairing data-driven insights with collaborative problem-solving discussions to drive therapeutic progress in Hidradenitis Suppurativa\, JAK Inhibitors and Assets Targeting Multiple Indications\, plus laying foundations for Recruitment and Retention finesse.\n\nIncreased drug development landscape visibility\, including clinical case studies from early to late-stage programs\, all with dedicated Q&A time\, for Monoclonal Antibodies\, Oral and Topical Small Molecules\, Oral Peptides\, siRNA Lipid Conjugates\, Bispecific Antibodies and more! \nHere’s a snapshot of who you will meet: \nTakeda | MoonLake Immunotherapeutics | Seagen | Astria Therapeutics | Aditum Bio | Shaperon | Lynk Pharma | CAGE Bio | Sanofi | Edesa Biotech | Arcutis Biotherapeutics | AbbVie | GSK | Carocell Bio | Enveda Biosciences | Zura Bio | Incyte | UNION Therapeutics | Merck | Hudson Therapeutics | J&J | LEO Pharma | Recludix Pharma | Lynk Pharmaceuticals \nStay ahead of the scientific and commercial challenges in inflammatory disease drug development to set yourself up for success in 2025! \nQuick links: Website | Event Guide | Contact Us
URL:http://www.pharmajournalist.com/event/8th-dermatology-drug-development-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241112
DTEND;VALUE=DATE:20241114
DTSTAMP:20260515T144750
CREATED:20240906T115503Z
LAST-MODIFIED:20240906T115503Z
UID:39712-1731369600-1731542399@www.pharmajournalist.com
SUMMARY:Advanced Therapies USA
DESCRIPTION:The Advanced Therapies Congress showcases the future of advanced therapies. Bringing Europe’s largest cell and gene therapy conference and exhibition to Philadelphia\, the event is for the leaders of the world’s ATMP developers and their most senior executives in charge of the latest tech and strategies that are driving the industry forward. This year\, we will be expecting 1000+ attendees\, 200 speakers\, 100+ sponsors and exhibitors\, join us now! \nTo know more visit: www.terrapinn.com/adtusa/pj/index 
URL:http://www.pharmajournalist.com/event/advanced-therapies-usa/
LOCATION:Pennsylvania Convention Center\, Philadelphia
END:VEVENT
END:VCALENDAR